Clinical trial of Lifitegrast in healthy subjects for safety and pharmacokinetic profile

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065043

Enrollment

Unknown

Registered

2022-10-26

Start date

2022-10-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndrome

Interventions

Intervention Group:Litasite Diyanye

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) Healthy Chinese males or females aged 18 to 45 (inclusive); 2) Body weight: male weight >= 50.0kg, female weight >= 45.0kg, body mass index 18.0~28.0kg/m2;

Exclusion criteria

Exclusion criteria: 1) Subjects with ocular/systemic diseases that are clinically significant according to the judgment of the investigator, including but not limited to Stevens-Johnson syndrome, conjunctival scar, cardiovascular system, endocrine system, digestive system, urinary system, hematological system, nervous system, immune system, metabolic disorders, malignant tumor, and other major diseases, or patients with mental disorders and other diseases that investigator considers inappropriate for clinical trials

Design outcomes

Primary

Measure	Time frame
maximum concentration;Maximum Temperature;Area under the curve;	—

Countries

China

Contacts

Public ContactLuozhu

West China Hopital of Sichuan University

769824157@qq.com13228212376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026